Interarch Building Solutions bags Rs 77-cr order from Amara Raja Infra
Interarch Building Solutions announced that it has secured an order worth Rs 77 crore from Amara Raja Infra.
The formal purchase order is currently awaited. According to an exchange filing, the contract involves the design, engineering, manufacturing, supply, and erection of a pre-engineered steel building system.
The firm also noted that it expects to receive a 10% advance payment along with the order. Interarch clarified that neither the promoter, promoter group, nor any group companies have any financial or other interest in the awarding entity.
The official announcement was made on 27 June 2025, after market hours.
Interarch Building Products is a leading provider of pre-engineered steel building solutions in India. The company possesses integrated capabilities encompassing design and engineering, manufacturing, and on-site project management for the installation and erection of pre-engineered steel structures.
The companys standalone net profit surged 30.2% to Rs 38.68 crore on a 20.2% increase in net sales to Rs 385.47 crore in Q4 FY25 compared to Q4 FY24.
The scrip rose 1.50% to settle at Rs 2,131.35 on Friday, 27 June 2025.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
5 minutes ago
- Economic Times
Zen Technologies shares gain over 3% after securing Indian patent in defence tech
Shares of Zen Technologies gained 3.5% on Monday to the day's high of Rs 1,992 after the company announced the grant of its 54th Indian patent. ADVERTISEMENT The newly awarded patent, titled 'Single ILU Long Pass Filter,' represents a notable advancement in laser-based military training systems and reinforces Zen's growing footprint in defence technology. With this addition, the company's total global patent count has reached 82, highlighting its strong focus on indigenous R&D and innovation in defence simulation. The patented technology enables the integration of visible and infrared laser beams into a single, stable output, enhancing the accuracy and realism of combat training simulators. Compared to traditional systems that rely on separate beams and are often prone to alignment issues and high maintenance, Zen's compact design promises greater durability and reduced recalibration needs, especially in rugged field conditions. This breakthrough strengthens Zen's portfolio of advanced training solutions, supporting the Indian armed forces and global defence clients with state-of-the-art simulation capabilities. The market responded positively to the development, with investors viewing the patent as a value-add in Zen's long-term growth a valuation standpoint, the stock is currently trading at a Price-to-Earnings (PE) ratio of 61.99 and a Price-to-Book (PB) ratio of 10.01, indicating a premium valuation likely driven by its strong growth potential and innovation the technical front, Zen is exhibiting a bullish trend based on moving averages. The stock is trading above 6 out of 8 key Simple Moving Averages (SMAs), including longer-term indicators, reflecting underlying strength. It is marginally below the 20-day and 30-day SMAs, which may be watched for short-term trend confirmation. (You can now subscribe to our ETMarkets WhatsApp channel)
News18
5 minutes ago
- News18
India's Agriculture GVA Triples In 12 Years: Official Data
Last Updated: Uttar Pradesh continues to lead the country in agricultural output, contributing 17% of the national GVO, followed by Madhya Pradesh, Punjab, Telangana, and Haryana. India's agriculture and allied sectors have seen their gross value added (GVA) more than triple over the past 12 years, reflecting the sector's growing economic footprint. According to a new report by the Ministry of Statistics and Programme Implementation, agri GVA rose to over Rs 48,00,000 crore in FY24 from around Rs 15,00,000 crore in FY12 — a surge supported by improved productivity and public policy push. Despite rapid industrialisation, agriculture continues to be the backbone of India's economy, contributing roughly 16% to GDP and sustaining more than 46% of the country's population. 'Gross Value Added (GVA) of agriculture and allied sectors at current prices registered a growth of about 225%, increasing from Rs 1,502 thousand crore in 2011-12 to Rs 4,878 thousand crore in 2023-24," the ministry said in the report titled 'Statistical Report on Value of Output from Agriculture and Allied Sectors'. The agriculture output or GVO at the real prices also surged 55% during the period, from Rs 1,908 thousand crore in 2011-12 to Rs 2,949 thousand crore in 2023-24, it added. According to analysts, favourable monsoons, expanded irrigation, and targeted government schemes like PM-KISAN and crop insurance have lifted productivity and incomes of farmers. Crops Remain Dominant, Cereals Lead According to the report, crop production forms the largest slice of agricultural GVO, accounting for over 54% of the total. Within this, cereals and fruits & vegetables make up over half of the value, with paddy and wheat alone contributing 85% of the cereal segment. Among fruits, bananas edged out mangoes in FY24 as the top value-generating fruit crop, clocking a GVO of Rs 47 thousand crore compared to mango's Rs 46.1 thousand crore. On the vegetable front, potato retained its crown, with GVO rising to Rs 37.2 thousand crore in FY24 from Rs 21.3 thousand crore in FY12. Uttar Pradesh continues to lead the country in agricultural output, contributing 17% of the national GVO. It is followed by Madhya Pradesh, Punjab, Telangana, and Haryana — collectively responsible for 53% of total output. The livestock sector also recorded strong growth, with its GVO rising from Rs 488 thousand crore in FY12 to Rs 919 thousand crore in FY24. Milk dominates the segment, though its share slightly dipped to 66% as meat production grew and now makes up 24%. Floriculture, though a smaller segment, has seen impressive gains — its GVO nearly doubled from Rs 17.4 thousand crore to Rs 28.1 thousand crore over the period, signalling growing commercial interest in diversified horticulture. A Cornerstone of Rural Prosperity The report underscores how agriculture is evolving — not just as a source of food but as a key player in rural employment, economic diversification, and national growth. From traditional grains to emerging segments like floriculture and livestock, the sector is transforming in both scale and scope. First Published:
Time of India
19 minutes ago
- Time of India
Alembic Pharma shares rally 12% on USFDA nod for cancer drug
Shares of Alembic Pharmaceuticals climbed as much as 12% on Monday to Rs 1,089.80 on BSE after the company received final approval from the US Food and Drug Administration (USFDA) for its generic version of Doxorubicin Hydrochloride Liposome Injection , a cancer treatment drug. In a press release issued Sunday, the company announced that it had received final USFDA approval for its Abbreviated New Drug Application (ANDA) for Doxorubicin Hydrochloride Liposome Injection, 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) single-dose vials. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like New Container Houses Indonesia (Prices May Surprise You) Container House | Search ads Search Now Undo The company noted, 'The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Doxil Liposome Injection, 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL), of Baxter Healthcare Corporation.' The injection is indicated for the treatment of ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma. 'Refer to label for detailed indication,' the company said. Citing IQVIA data, Alembic estimated the market size of Doxorubicin Hydrochloride Liposome Injection in the U.S. to be $29 million for the twelve months ending March 2025. Live Events Growing US pipeline Alembic's cumulative count of USFDA approvals now stands at 224 ANDAs, comprising 201 final approvals and 23 tentative approvals. Earlier this month, on June 18, the company also received an Establishment Inspection Report (EIR) from the USFDA for its API-III facility in Karakhadi, following an inspection conducted from March 17 to March 21, 2025. Stock performance and technicals Alembic's stock has been on a steady uptrend. It has gained 22.7% in the past year, 2.5% in the past six months, 15.7% over the last three months, and 6.8% in the past month. From a technical standpoint, the stock is currently trading above all its key simple moving averages (5-day to 200-day), signaling bullish momentum across time frames. The Relative Strength Index (RSI) is at 52.4, indicating neutral territory, while the Moving Average Convergence Divergence (MACD) is at 2.4, staying above its center line though still below its signal line. The stock hit a 52-week high of Rs 1,296.15 on October 9, 2024, and a 52-week low of Rs 725.60 on March 3, 2025. Also read | Godrej Properties shares in focus after Rs 600 crore Panipat land deal ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
